AI drug discovery company Earendil Labs inked a strategic collaboration with Sanofi to develop autoimmune and inflammatory disease treatments in a deal that could be worth up to $2.56 billion.
Why it matters: Today's agreement builds on a $1.8 billion exclusive licensing deal the two companies brokered last year to advance two Earendil autoimmune bispecific antibodies.
